Therapeutic Effects of Anti-CD115 Monoclonal Antibody in Mouse Cancer Models through Dual Inhibition of Tumor-Associated Macrophages and Osteoclasts

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Fend, Laetitia ^a   Accart, Nathalie ^a   Kintz, Jacqueline ^a   Cochin, Sandrine ^a   Reymann, Carine ^a   Le Pogam, Fabrice ^a   Marchand, Jean Baptiste ^a   Menguy, Thierry ^a   Slos, Philippe ^a   Rooke, Ronald ^a   Fournel, Sylvie ^b   Bonnefoy, Jean Yves ^a   Préville, Xavier ^a   Haegel, Hélène ^a  

^a TRANSGENE S A   (France)

^b Faculté de Pharmacie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD115 ANTIBODY; CD115 ANTIGEN; CELL ANTIGEN; CSF 1 PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AFS98; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG TARGETING; FEMALE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; OSTEOCLAST; PROTEIN BINDING; THERAPY EFFECT; TUMOR ASSOCIATED LEUKOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OSTEOCLASTS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SURVIVAL ANALYSIS;

EID: 84883362872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073310     Document Type: Article

References (53)

1. Condeelis J, Pollard JW, (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266.
2. Pollard JW, (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84: 623-630.
3. Yagiz K, Rittling SR, (2009) Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res 315: 2442-2452.
4. Solinas G, Germano G, Mantovani A, Allavena P, (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065-1073.
5. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, et al. (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4: e6562.
6. Sherr CJ, (1990) Colony-stimulating factor-1 receptor. Blood 75: 1-12.
7. Stanley ER (2000) CSF-1. In: J O, editor. Cytokine Reference: Academic press. 911-934.
8. Droin N, Solary E, (2010) Editorial: CSF1R, CSF-1, and IL-34, a "menage a trois" conserved across vertebrates. J Leukoc Biol 87: 745-747.
9. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML, (1997) Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 3: 999-1007.
10. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, et al. (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10: 173-177.
11. Smith HO, Anderson PS, Kuo DY, Goldberg GL, DeVictoria CL, et al. (1995) The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1: 313-325.
12. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, et al. (2008) Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 110: 445-451.
13. Kirma N, Hammes LS, Liu YG, Nair HB, Valente PT, et al. (2007) Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Cancer Res 67: 1918-1926.
14. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, et al. (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120-126.
15. Scholl SM, Crocker P, Tang R, Pouillart P, Pollard JW, (1993) Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol Carcinog 7: 207-211.
16. Lin EY, Nguyen AV, Russell RG, Pollard JW, (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740.
17. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246.
18. Aharinejad S, Abraham D, Paulus P, Abri H, Hofmann M, et al. (2002) Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res 62: 5317-5324.
19. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, et al. (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64: 7022-7029.
20. Hernandez L, Smirnova T, Kedrin D, Wyckoff J, Zhu L, et al. (2009) The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 69: 3221-3227.
21. Green CE, Liu T, Montel V, Hsiao G, Lester RD, et al. (2009) Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One 4: e6713.
22. Hamilton JA, (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8: 533-544.
23. Sica A, Schioppa T, Mantovani A, Allavena P, (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727.
24. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH, (2006) Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 79: 285-293.
25. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, et al. (2007) Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110: 4319-4330.
26. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, et al. (2005) Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 142: 481-489.
27. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, et al. (2009) Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 69: 9395-9403.
28. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, et al. (2009) The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 15: 778-787.
29. Hume DA, MacDonald KP, (2012) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119: 1810-1820.
30. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, et al. (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99: 111-120.
31. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, et al. (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190: 1741-1754.
32. Hodge JM, Collier FM, Pavlos NJ, Kirkland MA, Nicholson GC, (2011) M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One 6: e21462.
33. Takayanagi H, (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304.
34. Sudo T, Nishikawa S, Ogawa M, Kataoka H, Ohno N, et al. (1995) Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M. Oncogene 11: 2469-2476.
35. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, et al. (2005) Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65: 5278-5283.
36. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, et al. (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115: 3418-3427.
37. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
38. Cailleau R, Young R, Olive M, Reeves WJ Jr, (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661-674.
39. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, et al. (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126.
40. Bartocci A, Mastrogiannis DS, Migliorati G, Stockert RJ, Wolkoff AW, et al. (1987) Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A 84: 6179-6183.
41. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
42. Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, et al. (2009) Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 69: 9498-9506.
43. Abraham D, Zins K, Sioud M, Lucas T, Schafer R, et al. (2010) Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer 126: 1339-1352.
44. Abraham D, Krenn K, Seebacher G, Paulus P, Klepetko W, et al. (2004) Upregulated hypoxia-inducible factor-1 DNA binding activity to the vascular endothelial growth factor-A promoter mediates increased vascular permeability in donor lung grafts. Ann Thorac Surg 77: 1751-1755.
45. Lucas T, Abraham D, Untergasser G, Zins K, Hofer E, et al. (2009) Adenoviral-mediated endothelial precursor cell delivery of soluble CD115 suppresses human prostate cancer xenograft growth in mice. Stem Cells 27: 2342-2352.
46. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, et al. (2009) JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 8: 3151-3161.
47. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, et al. (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 206: 1089-1102.
48. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S, (2006) Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 66: 4349-4356.
49. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, et al. (2010) An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116: 3955-3963.
50. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
51. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC, (2010) Dysregulation of bone remodeling by imatinib mesylate. Blood 115: 766-774.
52. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, et al. (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757-766.
53. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, et al. (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 5: 2634-2643.